Temtokibart Biosimilar Monoclonal Antibody (IL-22Rα1) for Research

Cat No.: GMP-Bios-INN-1413

Anti-IL22RA1 therapeutic antibody (Pre-made Temtokibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Temtokibart (development codes LEO 138559/ARGX112) is a humanized monoclonal antibody targeting IL-22 receptor alpha (IL22RA1). It is developed by argenx and LEO Pharma for Atopic dermatitis in Phase II development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1413-1mg 1mg 3090
GMP-Bios-INN-1413-10mg 10mg
GMP-Bios-INN-1413-100mg 100mg
GMP-Bios-INN-1413-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Temtokibart biosimilar, Whole mAb, Anti-IL22RA1 Antibody: Anti-IL-22RA1/IL22RA1/Interleukin-22 receptor subunit alpha-1/IL-22 receptor subunit alpha-1 therapeutic antibody
INN Name Temtokibart
Target IL22RA1
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Lambda
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2023
Year Recommended 2023
Companies argenx;LEO Pharma
Conditions Approved na
Conditions Active Atopic dermatitis
Conditions Discontinued na
Production na
Development Tech na